Dr. P. Jijiya Bai*, Dr. Shyamala Srujana, Dr. R. Asok Kumar, Dr. O. Shravan Kumar


BACKGROUND: Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. It is the second most commonly diagnosed hematologic malignancy with an annual incidence and prevalence in the United States of approximately 15,000 and approximately 45,000, respectively. The incidence is higher with increasing age (median age at diagnosis 67 yr). Multiple Myeloma accounts for approximately 1% of all malignancies and 10% of hematological malignancies, representing the second most frequently occuring hematological malignancy in the united states.[1] Aims & Objectives: 1) To study hematological findings and biochemical parameters in plasma cell Myeloma. 2) To determine optimal diagnostic markers. 3) Evaluation by international staging system. Materials & Methods: A total of 2458 hemograms over a period of 2 years were studied. 24 cases showed rouleaux formation & increased ESR. These cases were further evaluated with clinical history, hematological investigations, biochemical analysis and radiological findings. Results: 24 cases were analyzed, which showed raised ESR and severe anemia in all the cases. Haematological investigations including bone marrow examination, urine examination confirmed the diagnosis and all the pateints were graded according to recent staging system. Conclusion: Current research goals are to further increase our knowledge, to identify additional targeted therapies, and to reduce adverse effects and improve response rate. This review focuses on recent clinical advancement in myeloma strategies with additional discussion dedicated to emerging drugs that may prove beneficial to patients with this disease.

Keywords: Plasma cell neoplasm, multiple Myeloma post germinal center B cell.

[Full Text Article]   [Download Certificate]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    MAY 2024 Issue has been successfully launched on 1 MAY 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction